Absolute Neutrophil Counts in a Study of Lipegfilgrastim Compared with Pegfilgrastim in Patients with Breast Cancer Who are Receiving Chemotherapy

Gladkov, Oleg; Bondarenko, Igor; Elsaesser, R.; Buchner, Anton; Bias, Peter

doi:10.1016/s0923-7534(20)34120-x

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of treatment-related AEs was similar for balugrastim and pegfilgrastim (20 % vs 19 %) [18]. The second RCT found similar durations of severe neutropenia for balugrastim and pegfilgrastim (1.3 days vs 1.2 days) [19].…”

Section: Balugrastimmentioning

confidence: 85%

“…After removing duplicates, 700 items were left, of which 482 were excluded on the basis of title and abstract screening, leaving 218 articles (Online Resource 3). Three relevant articles were published after completion of the search: Bondarenko et al (2013) [16], Almenar-Cubells et al (2013) [17] and Volovat et al (2013) [18]; these were included to replace congress abstracts identified by the initial search that described the same studies [19][20][21]. Finally, 33 publications and 11 congress abstracts representing 41 studies were analysed.…”

Section: Eligible Trials and Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review

Pfeil

Allcott

Pettengell

et al. 2014

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Balugrastimmentioning

confidence: 85%

Section: Eligible Trials and Study Characteristicsmentioning

confidence: 99%

Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review

Pfeil

Allcott

Pettengell

et al. 2014

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement

Petru

Singer

Polterauer

et al. 2015

Wien Med Wochenschr

View full text Add to dashboard Cite

We reviewed the status of the use of the prophylactic long-acting granulocyte colony-stimulating factors (G-CSFs) pegfilgrastim and lipegfilgrastim in gynecologic malignancies. Long-acting G-CSFs should not be used in weekly regimens. Filgrastim is not indicated in patients with febrile and/or severe neutropenia after administration of long-acting G-CSF in the same cycle. One study has shown a moderate effect on febrile neutropenia of ciprofloxacin when co-administered with pegfilgrastim. There is broad evidence from meta-analyses that pegfilgrastim effectively reduces severe neutropenia. In parallel, its adverse effects have been studied extensively. All-cause mortality was significantly reduced by pegfilgrastim. The glycopegylated long-acting G-CSF, lipegfilgrastim has demonstrated antineutropenic efficacy similar to that of pegfilgrastimin in one breast cancer study. In another pivitol non-small cell lung cancer study, impaired survival was observed in the lipegfilgrastim group during the first 30 days of study. The European Medicines Agency claimed more profound safety data to be provided for lipegfilgrastim by 2017.

show abstract

Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia

Ratti

Tomasello²

2014

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Chemotherapy is frequently associated with hematologic toxicity. Neutropenia with or without fever is a relevant cause of morbidity, mortality and costs, compromising treatment administration and clinical outcomes. The development of granulocyte colony-stimulating factors has had a positive impact on the clinician's approach to neutropenia. Such agents, currently used for primary and secondary prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia (FN), are effective in limiting hematologic toxicities and consequently allow the administration of intensive dose-dense regimens. Several biosimilar products of filgrastim have been developed over the years, showing effects similar to the originator drug. Until now, pegfilgrastim has been the only available long-acting factor, requiring just a single administration per chemotherapy cycle. The recent approval of the novel granulocyte colony-stimulating factors, lipegfilgrastim, offers interesting therapeutic alternatives. In fact, similar to pegfilgrastim, it has been demonstrated to reduce the duration of neutropenia and the occurrence of FN during chemotherapy safely.

show abstract

Absolute Neutrophil Counts in a Study of Lipegfilgrastim Compared with Pegfilgrastim in Patients with Breast Cancer Who are Receiving Chemotherapy

Cited by 4 publications

References 0 publications

Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review

Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review

Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement

Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia

Contact Info

Product

Resources

About